Count rate measurement device and associated fission chamber calibration device
    1.
    发明授权
    Count rate measurement device and associated fission chamber calibration device 有权
    计数速率测量装置及相关的裂变室校准装置

    公开(公告)号:US09188684B2

    公开(公告)日:2015-11-17

    申请号:US12809574

    申请日:2008-12-22

    IPC分类号: G01T3/00 G01T1/185 G21C17/108

    CPC分类号: G01T3/00 G01T1/185

    摘要: A fission chamber count rate measurement device and to the associated fission chamber calibration device; the count rate measurement device comprises: (1) a measurement cell, which contains the fission chamber (CH); (2) a neutron generator, which emits neutrons in the form of periodic pulses towards the fission chamber; (3) a neutron counter (K), which detects and counts the neutrons emitted by the neutron generator; and (4) a computing circuit, which delivers, over a predetermined time interval, a fission chamber count rate normalized with reference to the number of neutrons counted by the neutron counter (K).

    摘要翻译: 裂变室计数率测量装置和相关的裂变室校准装置; 计数率测量装置包括:(1)包含裂变室(CH)的测量单元; (2)中子发生器,其以朝向裂变室的周期性脉冲的形式发射中子; (3)中子计数器(K),用于检测和计数由中子发生器发射的中子; 和(4)计算电路,其以预定的时间间隔递送参考由中子计数器(K)计数的中子数量归一化的裂变室计数速率。

    PEPTIDE-BASED COMPOUNDS AS NEW INHIBITORS OF METALLOECTOPEPTIDASES, COMPOSITIONS COMPRISING SAID COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMETIC USES

    公开(公告)号:US20100062052A1

    公开(公告)日:2010-03-11

    申请号:US12524955

    申请日:2008-02-04

    申请人: Philippe Bernard

    发明人: Philippe Bernard

    摘要: The invention relates to a compound that inhibits a metallo-ectopeptidase, selected in the group consisting of x-aa2-aa1-z, x-aa3-aa2-aa1-z, x-aa4-aa3-aa2-aa1-z and x-aa5-aa4-aa3-aa2-aa1-z, wherein: aa1 and aa4, independently from each other, represent an arginine amino acid, an histidine amino acid, an asparagine amino acid or a lysine amino acid, aa2 represents a serine amino acid, a glycine amino acid, a threonine amino acid or an alanine amino acid, aa3 represents a phenylalanine amino acid, a leucine amino acid, an isoleucine amino acid, a tyrosine amino acid or a tryptophan amino acid, aa5 represents a glutamine amino acid, a glutamic acid amino acid, an asparagines amino-acid or a lysine amino acid, x and z, independently from each other, represent: —H; —OH1 SH; —a halogen atom, —an amino group, —an alkyl, haloalkyl or heteroalkyl group containing from 1 to 30 carbon atoms, linear or branched, —an alkenyl or alkynyl group containing from 2 to 30 carbon atoms, linear or branched, —a cycloalkyl, cycloakenyl, cycloalkynyl or an heterocyclic group containing from 3 to 30 carbon atoms, linear or branched, —one or more aryl or heteroaryl groups containing from 3 to 10 carbon atoms per cycle, —a alkoxy, thioalkyl, sulfonylalkyl, aminoalkyl containing from 1 to 30 carbon atoms, linear or branched, —one or more heterocyclic group, containing from 5 to 10 carbon atoms per cycle, said groups being optionally substituted by one or more halogen atoms, alkyl groups, hydroxy groups, alkoxy groups, aryloxy groups, acyloxy groups, carbamoyloxy groups, carboxy groups, mercapto groups, alkylthio groups, acylthio groups, arylthio groups, aryl groups, heterocyclic groups, heteroaryl groups or amino groups.

    Cloning and/or sequencing vector
    4.
    发明授权
    Cloning and/or sequencing vector 失效
    克隆和/或测序载体

    公开(公告)号:US5910438A

    公开(公告)日:1999-06-08

    申请号:US379614

    申请日:1995-07-20

    CPC分类号: C12N15/70

    摘要: A cloning and/or sequencing vector (1) comprises a nucleotide promoter sequence (3) and a nucleotide sequence (4) coding for a fusion protein active as a poison, which nucleotide sequence (4) is obtained by fusion of a coding nucleotide sequence (5) containing several unique cloning sites with a nucleotide sequence (6) coding for a poison protein, wherein the nucleotide sequences (3) and (4) are incorporated in an autonomous replication vector (2).

    摘要翻译: PCT No.PCT / BE93 / 00051 Sec。 371日期1995年7月20日 102(e)日期1995年7月20日PCT 1993年8月2日PCT公布。 第WO94 / 03616号公报 日期1994年2月17日克隆和/或测序载体(1)包含核苷酸启动子序列(3)和编码作为毒物活化的融合蛋白的核苷酸序列(4),该核苷酸序列(4)通过融合获得 的编码核苷酸序列(5),其含有编码毒蛋白的核苷酸序列(6)的几个独特的克隆位点,其中所述核苷酸序列(3)和(4)并入自主复制载体(2)中。

    Hydrogen reduction of carbonaceous source to form carbon monoxide
    5.
    发明授权
    Hydrogen reduction of carbonaceous source to form carbon monoxide 失效
    碳源的氢还原形成一氧化碳

    公开(公告)号:US4758249A

    公开(公告)日:1988-07-19

    申请号:US4246

    申请日:1987-01-05

    摘要: Carbon dioxide is facilely converted into carbon monoxide and water, and advantageously into a syngas, by establishing a thermally homogeneous gaseous admixture including carbon dioxide and hydrogen having a temperature of at least 800.degree. C., within a period of time essentially insufficient for the production of carbon monoxide therefrom, and wherein said carbon dioxide is next autogenously reduced under reaction equilibrium conditions to carbon monoxide and water by reaction with hydrogen, with each molecule of carbon monoxide formed having, or essentially instantaneously being brought to, a temperature of at least 800.degree. C.

    摘要翻译: 通过在基本上不足以用于生产的时间内建立包含二氧化碳和至少800℃温度的氢的热均匀气体混合物,将二氧化碳容易地转化为一氧化碳和水,并有利地转化为合成气 的一氧化碳,并且其中所述二氧化碳接着在与氢气反应的反应平衡条件下自发还原成一氧化碳和水,每分子形成的一氧化碳分别具有或基本上瞬间地达到至少800 DEG C.

    DEVICE FOR MEASURING COMPLIANCE WITH OXYGEN THERAPY USING A THREE-DIMENSIONAL ACCELEROMETER
    7.
    发明申请
    DEVICE FOR MEASURING COMPLIANCE WITH OXYGEN THERAPY USING A THREE-DIMENSIONAL ACCELEROMETER 审中-公开
    使用三维加速度计测量符合氧气治疗的装置

    公开(公告)号:US20130310713A1

    公开(公告)日:2013-11-21

    申请号:US13983217

    申请日:2012-01-11

    IPC分类号: A61B5/00 A61B5/11 A61M16/00

    摘要: The invention relates to a device for measuring patient compliance with oxygen therapy, including a casing (4) comprising means for detection of the oxygen therapy in order to evaluate data relating to the treatment; and means for measuring a state of physical activity of the patient. Preferably, the means for measuring a state of physical activity of the patient comprise at least one sensor which senses movement of the patient's body and outputs data relating to the spatial displacement of the patient's body, for example a three-dimensional accelerometer (28); and processing means (40, 42) for processing the body displacement data in order to supply a state of physical activity of the patient chosen from a sleeping state, a resting state and an active state.

    摘要翻译: 本发明涉及一种用于测量患者对氧疗的依从性的装置,包括壳体(4),其包括用于检测氧疗的装置,以便评估与治疗有关的数据; 以及用于测量患者的身体活动状态的装置。 优选地,用于测量患者的身体活动状态的装置包括至少一个感测患者身体运动的传感器,并且输出与患者身体例如三维加速度计(28)的空间位移有关的数据。 以及用于处理身体位移数据以便提供从休眠状态,静止状态和活动状态中选择的患者的身体活动状态的处理装置(40,42)。

    Use of silymarin and/or constituents thereof as skin or hair pigmentation promoters
    8.
    发明授权
    Use of silymarin and/or constituents thereof as skin or hair pigmentation promoters 有权
    使用水飞蓟素和/或其成分作为皮肤或毛发色素启动子

    公开(公告)号:US08569358B2

    公开(公告)日:2013-10-29

    申请号:US11818943

    申请日:2006-02-13

    IPC分类号: A01K43/32 A61K31/335

    摘要: Describe is a method of administering to a subject silymarin, or of the main constituents thereof alone or as a mixture, chosen from silybin (or 2,3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6-(3, 5,7-trihydroxy-4-oxobenzopyran-2-yl)benzodioxine), isosilybin, silydianin, silychristin, silandrin, silymonin and taxifolin, isolated enantiomers thereof and also salts thereof.

    摘要翻译: 描述是向受试者水飞蓟素或其主要成分单独或作为混合物施用水飞蓟宾(或2,3-二氢-3-(4-羟基-3-甲氧基苯基)-2-(羟甲基 )-6-(3,5,7-三羟基-4-氧代苯并吡喃-2-基)苯并二氧杂环己烯),异水松杉碱,硅藻土,水滑石,丝兰蛋白,silymonin和taxifolin,其分离的对映体及其盐。

    PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCY
    9.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL DEPENDENCY 审中-公开
    用于治疗酒精依赖性的药物组合物

    公开(公告)号:US20120289514A1

    公开(公告)日:2012-11-15

    申请号:US13519042

    申请日:2010-12-29

    摘要: Pharmaceutical composition for treating alcohol dependence in humans comprising two active ingredients: a compound having an antagonistic action on the 5-HT2 serotoninergic receptors selected as being cyproheptadine; and a compound having an antagonistic action on the alpha1-noradrenergic receptors selected from prazosin, alfuzosin, terazosin and tamsulosin.

    摘要翻译: 用于治疗人类酒精依赖性的药物组合物,其包含两种活性成分:对选择为赛庚啶的5-HT2血清素能受体具有拮抗作用的化合物; 以及对选自哌唑嗪,阿夫唑嗪,特拉唑嗪和坦索罗辛的α1-去甲肾上腺素能受体具有拮抗作用的化合物。

    Mobile floor for swimming pool
    10.
    发明申请
    Mobile floor for swimming pool 审中-公开
    手机地板游泳池

    公开(公告)号:US20120131742A1

    公开(公告)日:2012-05-31

    申请号:US13274165

    申请日:2011-10-14

    申请人: Philippe BERNARD

    发明人: Philippe BERNARD

    IPC分类号: E04H4/14

    CPC分类号: E04H4/065

    摘要: A mobile floor device for a swimming pool including a stationary floor, standing lateral walls, a mobile floor and a mechanism for pulling said mobile floor. The pulling mechanism includes cables and drivers driving the cables in one direction or in a reverse direction. Each cable having a first end connected to the mobile floor and a second end connected to the swimming pool. For each cable, at least one driver drives a maximum of one cable. The drivers are attached either to the swimming pool or to the mobile floor with the lengths of the cables between the drivers and the mobile floor and the swimming pool, respectively, being substantially equal to one another.

    摘要翻译: 一种用于游泳池的移动地板装置,包括固定地板,站立侧壁,移动地板和用于拉动所述移动地板的机构。 牵引机构包括沿一个方向或相反方向驱动电缆的电缆和驱动器。 每个电缆具有连接到移动地板的第一端和连接到游泳池的第二端。 对于每根电缆,至少有一个驱动器最多可以驱动一根电缆。 驱动器分别连接到游泳池或移动地板上,其中驱动器与移动地板和游泳池之间的电缆的长度彼此基本相等。